Pain, sifness of joints, and funcional disability of rheumatoid arthriis (RA) are maximum in the morning. Cytokines, especially interleukin (IL)-6, demonstrate a circadian variaion in paients with RA and contribute to the severity of aforemenioned symptoms. Perturbed corisol response in paients with RA is not efecively able to negate the efects of interleukin 6 rise in the early morning. Modiied-release (MR) prednisone is a polymer-based drug delivery system which releases the drug 4 h ater the ingesion of tablet closely simulaing the corisol rise and peak in paients with RA. In this review, we focus on the raionale for chronotherapy, mechanisic consideraions, and clinical implicaions of MR prednisone.
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Introducion
Rheumatoid arthriis (RA) is a chronic systemic autoimmune inlammatory disease which is associated with progressive disability, poor quality of life, and systemic complicaions. Glucocoricoids (GCs) with their muliple mechanisms of acion are an efecive tool to treat RA. [1, 2] Available evidence also underscores their disease-modifying efect on the structural damage in RA without any convincing toxicity when used in low doses. [3, 4] Three factors, namely, GC resistance, concerns regarding toxicity of GC, and unproven superiority and safety of GC molecules such as Delazacort, coninue to drive the quest to develop GCs with beter risk-beneit raio. [1, 5, 6] Novel GCs that induce transrepression but simulate litle or no transacivaion are invesigated. In addiion, novel drug delivery systems and combinaions are also being developed. In this review, we appraise a novel drug delivery system of prednisone, i.e., modiied-release (MR) prednisone.
Circadian Rhythms in Rheumatoid Arthriis
Various diurnal variaions or circadian rhythms of the human body are rooted to the suprachiasmaic nucleus (SCN) in the hypothalamic region of the brain. Sleep-wake cycle, body temperature, heart rate, blood pressure, hormone regulaion, and immunity are the physiological funcions that fall under the purview of circadian control. [7] The SCN and paraventricular nucleus modulate circadian rhythms in the sympatheic and parasympatheic neurons, thereby inluencing diurnal variaions in gene transcripion in diferent lymphoid issues (which regulate the immune system) through posiive modulators (CLOCK; circadian locomotor output cycles kaput and BMAL1; brain and muscle aryl hydrocarbon receptor nuclear translocator like-1) and negaive regulators (PER; period and CRY; cryptochrome). [8] Reduced producion of corisol in the early morning and increased producion of melatonin in the night inluence the severity of early morning symptoms of RA. [9] The hypothalamic-pituitary-adrenal (HPA) axis and its associated circadian variaions in corisol (which can counter the efects of increased interleukin [IL-6] levels) are also disturbed in RA. [10] In one of the early studies, a diurnal variaion in the grip strength and joint sifness in RA was reported. [11] There was about 28% improvement in grip strength at 6.00 pm compared to 6.00 am and the joint sifness reduced by 40% at 6.00 pm compared to 6.00 am. [11] In another study, paients reported minimal grip strength and maximal joint swelling in the morning, while subjecive pain and sifness scores were also highest in the morning. [12] Alteraions in circadian rhythm of circulaing serum corisol, melatonin, and IL-6 correlate with the hypofuncioning of the HPA axis in paients with RA. [13] The corisol peak and nadir shited to earlier imes of the day in those paients with low erythrocyte sedimentaion rates (ESRs up to 40 mm/h) and medium disease acivity (ESR between 40 and 80 mm/h) in a study. [13] On the contrary, the circadian rhythm was lost or markedly reduced in paients with high acivity (i.e., those with >80 mm/h). [13] In another study, a signiicant correlaion was also noted between inlammatory acivity in RA and adrenal corisol secreion (coeicient of regression r = 0.63, n = 26, P < 0.001). [14] IL-6 is a potent acivator of the HPA axis as well as an important systemic mediator of the acute phase response in acive RA. In one study, IL-6, ESR, and C-reacive protein (CRP) signiicantly correlated with serum corisol, which is elevated in acive RA, depending on disease acivity. [15] In another study in comparison to normal subjects, plasma IL-6 levels were signiicantly elevated in paients with RA with a circadian rhythm observed [ Figure 1 ]. [16] Melatonin works on immune system by regulaing cytokine producion of immunocompetent cells. Melatonin simulates the producion of IL-2, interferon γ, IL-12, and IL-6. [17] The concentraion of these cytokines peaks in the early morning, and at the same ime, the serum melatonin levels also peaks. In fact, the melatonin levels have been found to be signiicantly higher in paients with RA compared to controls. Although progressive increase in melatonin was observed in those with RA and control subjects from 8.00 pm up to 1 st h of the morning, the peak serum melatonin concentraion was reached earlier by at least 2 h in RA paients than in control subjects (P < 0.05). The melatonin plateau was sustained for 2-3 h in RA paients but not in control subjects. Ater 2.00 pm, there was no diference in decrease of melatonin levels in both RA paients and control subjects. [18] Hence, the nocturnal melatonin rhythm is altered in paients with RA with earlier peak and a longer duraion in the early morning.
Prolacin is also thought to have a pathogenic role in RA. [19] The prolacin levels were found to be elevated in the serum as well as in the synovial luids in paients with RA. [20] A signiicant correlaion was found between high prolacin levels and the duraion of RA (r = 0.23; P = 0.01) as well as funcional stage (r = 0.24; P = 0.01). [21] 
Chronotherapy with Glucocoricoids
Chronotherapy exploits the known disturbed circadian rhythms to opimize treatment outcomes and minimize adverse efects. Aforemenioned observaions suggest that the opimal ime for delivery of GC treatment is during the night, to mimic the normal circadian rhythm of corisol secreion and target the efects of nocturnal proinlammatory simuli. The iniial chronotherapies involving GCs were imed in the morning, which coincided with the commencement of diurnal acivity of RA symptoms. [22] A trial tested administraion of low-dose prednisolone (5 or 7.5 mg daily) at 2.00 am which showed favorable efects on the duraion of morning sifness, joint pain, aricular indices, and morning serum concentraions of IL-6 (P < 0.01). [22] In the 1980's, a unique twice-a-day GC combinaion chronotherapy (Duimelan 8-15™) was introduced to mimic the endogenous circadian corisol rhythm. The 8.00 am tablet contained 7 mg prednisolone acetate plus 4 mg prednisolone alcohol and 3.00 pm tablet contained 3 mg prednisolone alcohol and 15 mg prednisolone acetate. As safe as the convenional GCs, it fell out of favor due to poor paient compliance. [23] In a subsequent study, no diference in the circadian rhythms of inger joint swelling and of grip strength was noted when the GC was dosed at diferent imes (once-daily at 8.00 am, 1.00 pm, or 11.00 pm). [24] However, in a diferent study, nighime dosing of low-dose GCs signiicantly reduced the duraion of morning sifness when compared to morning-ime once-daily, driving home the point that the opimum ime of GC dosing is at night. [25] 
Modiied-release Prednisone
The main diference between MR prednisone and convenional/immediate-release (IR) prednisone is the ime-delayed release of the acive agent. Following oral ingesion (at 10.00 pm) of the MR tablet of prednisone, water penetrates the tablet as it passes through the gastrointesinal tract and the coaing bursts approximately 4 h ater the ingesion and releases prednisone at about 2.00 am. [26] This closely simulates the normal physiological rise of corisol which negates the IL-6-related early morning disease manifestaions of RA.
Clinical Eicacy of Modiied-release Prednisone a. Randomized controlled studies
Circadian Administraion of Prednisone in Rheumatoid Arthriis (CAPRA-1) was a 12-week, mulicenter, randomized, double-blind trial which compared the eicacy of MR prednisone with that of IR prednisone in 288 paients with acive RA who were receiving stable doses of disease-modifying anirheumaic drugs (DMARDs). [27] Their average daily duraion of morning sifness was 45 min or more. [27] 12 weeks of treatment with evening administraion of MR prednisone resulted in a substanially greater decrease in duraion of morning sifness of the joints than was recorded ater morning administraion of IR prednisone (relaive change; from baseline 164.1 [101.4] min vs. 182.5 [125.0] min to at the study end − 22.7% [89.1] min vs. −0.4% [89.0] min, P = 0.045). [27] At the end of treatment, paients in the prednisone MR group achieved a mean reducion of 44 min in the morning sifness compared with baseline. This improvement in morning sifness with MR prednisone was already evident ater 2 weeks of treatment, with a diference of 10% between the two treatment groups. With coninued treatment, this diference increased and plateaued at around 38% from week 7 to the end of the 12-week treatment period. However, secondary outcomes for eicacy such as pain intensity during the day, quality of sleep, DAS28, physician's global assessment of disease acivity, laboratory variables (ESR, CRP), and health assessment quesionnaire disability index did no difer between the two groups. [27] CAPRA-2 invesigated the eicacy and safety of low-dose prednisone chronotherapy in paients with acive RA receiving standard DMARD treatment in a 12-week, double-blind, randomized, parallel-group, placebo-controlled mulicenter study. [28] At week 12, 48% of paients receiving MR prednisone achieved an ACR20 response, compared with 29% in the placebo group (P < 0.001). [28] The response was achieved rapidly: A signiicant diference in ACR20 response rate between treatment groups was evident at week 2, and the diference remained signiicant throughout the study (P < 0.005). ACR50 responder rates were numerically greater with MR prednisone than with placebo at all ime points, and the diference was signiicant at weeks 6 and 12 (22% vs. 10% at week 12, P < 0.006). [28] Signiicantly greater decreases in the severity of morning sifness and recurrence of sifness later in the day were also seen for MR prednisone compared with placebo (P ≤ 0.01) as well as in the morning and evening pain.
b. Switching to modiied-release prednisone
Of paients with RA originally randomized to MR or IR prednisone, all eligible 249 paients received MR prednisone chronotherapy (2-10 mg/day) in the 9-month open-label extension of CAPRA-1. [29] Irrespecive of whether paients were coninued on MR prednisone (MR/MR group) or switched from IR to MR prednisone (IR/MR group), there was sustained reducion in morning sifness. Ater 6 months of treatment, morning sifness was reduced in the IR/MR group by 54% and in the MR/MR group by 56%; morning sifness reducion ater 12 months was 45% in IR/MR group and 55% in MR/MR group. [29] DAS28 and pain showed clinically relevant improvements with no diferences between the treatment groups. Of the 219 paients who completed the enire study, 37% achieved an ACR20 response. [29] In an open-label observaional study, 950 RA outpaients who were treated with GCs and DMARDs were switched from IR prednisone or 6-methyl (6M)-prednisolone to low-dose MR prednisone and followed for 4 months. [30] At 4 months, treatment with MR prednisone signiicantly decreased the duraion of morning sifness [ Figure 2 ]. [30] Switching over to MR prednisone signiicantly alleviated the intensity of pain as measured on numerical raing scale [ Figure 3 ]. [30] Paient and physician global assessment scores of disease acivity also improved signiicantly from baseline (P < 0.001). [30] 
Efect of modiied-release prednisone on cytokines and hormones
In the CAPRA-1 study, IL-6 levels decreased in MR prednisone group but remained constant in the IR group (relaive reducion of nearly 29% vs. 0%). [27] In the long-term extension of the CAPRA-1 study, the same reducion by about 50% was seen at the end of the study in the IR/MR group. [29] Low levels of IL-6 were sustained, but no further reducion was observed in the MR/MR group. [29] In CAPRA-2 study compared to placebo, the decrease in IL-6 was greater in the MR prednisone group. [28] No change in the TNFα levels was observed between the two treatment arms. [28] In another study, the high pretreatment peak of IL-6 was abolished following treatment with MR prednisone. [31] Moreover, the changes in IL-6 correlated with the changes in morning sifness. There was a reducion in aternoon and evening serum corisol, but the early morning corisol peak concentraion increased. [31] 
Safety and tolerability of modiied-release prednisone
Treatment-emergent adverse events (AEs) during the 12-week blinded period in CAPRA-1 were not diferent between MR and IR prednisone groups. [27, 32] In the long-term extension of this study, the median duraion of exposure to MR prednisone was 281 days and the mean dose was 6.8 mg/day. [29] In CAPRA-2 study, the overall incidence of AEs was slightly lower in paients receiving MR prednisone than in those receiving placebo, and none of the serious or severe AEs in the MR prednisone group was considered related to treatment. [28] In addiion, there was no evidence for an increased risk of infecion with acive treatment. [28] On analyzing the results of aforemenioned studies, overall, the safety and tolerability of MR prednisone appear similar to IR/convenional prednisone as reported in the literature. [2, 4, 33, 34] 
Efect of chronotherapy with modiied-release prednisone on hypothalamic-pituitary-adrenal axis
Treatment with exogenous GCs afects the HPA; however, chronotherapy with MR prednisone had no AE on the HPA axis funcion. [27] In another study, over a period of 12 months, no deterioraion or onset of adrenal insuiciency was reported. [34] There was no diference in the mean corisol response between ime points [ Figure 4 ]. [35] In the long-term extension of CAPRA-1, no signs or symptoms were noted that might indicate aggravaion of suppression of the HPA axis. [29] Moreover, there was a 12% increase in maximum corisol response (from 12 weeks to 9 months) in those who shited to MR prednisone ater being treated with IR prednisone for 12 weeks. [28, 36] This suggests an improvement rather than deterioraion in the responsiveness of HPA axis in paients with RA receiving chronotherapy with MR prednisone compared to convenional morning prednisone treatment. [36] 
Conclusion
Awareness of the associaion between altered circadian patern of cytokines and hormones, and disease acivity in RA has resulted in a new treatment paradigm; the chronotherapy with MR prednisone. Synchronizing the iming of GC therapy with the nocturnal increase in blood IL-6 levels leads to alleviaion of pain and sifness far beter that a morning dose of convenional prednisone. MR formulaion of prednisone that is administered in the night at 10.00 pm is biologically available at 2.00 am, and this ime of release is ideal to counter the circadian rise in pro-inlammatory cytokine levels. There is evidence from mechanisic studies that the increase in IL-6 was indeed almost completely suppressed and HPA axis responsiveness was not suppressed and may even be enhanced by 2.00 am prednisone. Toxicity of this imed release is similar to convenional IR prednisone. A switch from IR/convenional prednisone to MR prednisone can be made and leads to improvement in troublesome morning sifness. MR prednisone therefore appears to be a useful addiion to the armamentarium used in the treatment of RA along with therapy with DMARDs.
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